For small cell lung cancer!

ArticleMedicine Guanlan

On October 22, Wanchun Medicine announced that the investigator-initiated prinabulin combined with nivolumab + ipilimumab can treat the third-line relapsed small cells that have failed in previous immune checkpoint inhibitors and platinum-based chemotherapy.

Plenabulin is a potential "first-in-class" immuno-antitumor drug first discovered in the natural marine product Halimide

Regarding the completion of the first patient administration of pranablin in the Phase 2 SCLC clinical trial, the principal investigator of the Rutgers Cancer Institute in New Jersey and medical oncologist Dr.

In this phase 2 study, as many as 26 patients with extensive-stage SCLC who have progressed with at least one platinum-based chemotherapy regimen and immune checkpoint inhibitors with histologically or cytologically confirmed treatment will be enrolled and receive Pranabrin+ Nivolumab + Ipilimumab triple therapy

Reference materials:

[1] The Phase 2 clinical study of Pranabrin combined with nivolumab + ipilimumab in the treatment of third-line relapsed small cell lung cancer patients with previous immune checkpoint inhibitors failed to complete the first patient administration.

(The original text has been deleted)